PDB Short entry for 4APJ HEADER HYDROLASE/HORMONE 03-APR-12 4APJ TITLE HUMAN ANGIOTENSIN-CONVERTING ENZYME IN COMPLEX WITH BPPB COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANGIOTENSIN-CONVERTING ENZYME; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: EXTRACELLULAR DOMAIN, RESIDUES 68-656; COMPND 5 SYNONYM: ACE, DIPEPTIDYL CARBOXYPEPTIDASE I, KININASE II, CD143, ACE- COMPND 6 T; COMPND 7 EC: 3.2.1.-, 3.4.15.1; COMPND 8 ENGINEERED: YES; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: BRADYKININ-POTENTIATING PEPTIDE B; COMPND 11 CHAIN: P; COMPND 12 SYNONYM: POTENTIATOR B; COMPND 13 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: CRICETULUS GRISEUS; SOURCE 6 EXPRESSION_SYSTEM_COMMON: CHINESE HAMSTER; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 10029; SOURCE 8 MOL_ID: 2; SOURCE 9 SYNTHETIC: YES; SOURCE 10 ORGANISM_SCIENTIFIC: GLOYDIUS BLOMHOFFI; SOURCE 11 ORGANISM_COMMON: MAMUSHI; SOURCE 12 ORGANISM_TAXID: 242054 KEYWDS HYDROLASE-HORMONE COMPLEX, ZINC METALLOPROTEASE, METALLOPEPTIDASE EXPDTA X-RAY DIFFRACTION AUTHOR G.MASUYER,S.L.U.SCHWAGER,E.D.STURROCK,R.E.ISAAC,K.R.ACHARYA REVDAT 5 20-DEC-23 4APJ 1 HETSYN REVDAT 4 29-JUL-20 4APJ 1 COMPND REMARK HETNAM LINK REVDAT 4 2 1 SITE ATOM REVDAT 3 11-MAR-20 4APJ 1 SEQRES LINK REVDAT 2 24-OCT-12 4APJ 1 JRNL REVDAT 1 17-OCT-12 4APJ 0 JRNL AUTH G.MASUYER,S.L.U.SCHWAGER,E.D.STURROCK,R.E.ISAAC,K.R.ACHARYA JRNL TITL MOLECULAR RECOGNITION AND REGULATION OF HUMAN ANGIOTENSIN-I JRNL TITL 2 CONVERTING ENZYME (ACE) ACTIVITY BY NATURAL INHIBITORY JRNL TITL 3 PEPTIDES. JRNL REF SCI.REP. V. 2 717 2012 JRNL REFN ESSN 2045-2322 JRNL PMID 23056909 JRNL DOI 10.1038/SREP00717 REMARK 2 REMARK 2 RESOLUTION. 2.60 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0109 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.60 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 71.82 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 96.9 REMARK 3 NUMBER OF REFLECTIONS : 18936 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.217 REMARK 3 R VALUE (WORKING SET) : 0.215 REMARK 3 FREE R VALUE : 0.256 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1028 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.60 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.67 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1345 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 96.32 REMARK 3 BIN R VALUE (WORKING SET) : 0.2370 REMARK 3 BIN FREE R VALUE SET COUNT : 93 REMARK 3 BIN FREE R VALUE : 0.3180 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4833 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 99 REMARK 3 SOLVENT ATOMS : 124 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 25.60 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.67000 REMARK 3 B22 (A**2) : -0.16000 REMARK 3 B33 (A**2) : 0.84000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.354 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.248 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 24.515 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.908 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.868 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 5085 ; 0.006 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 6905 ; 0.976 ; 1.959 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 591 ; 4.823 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 250 ;34.841 ;24.240 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 823 ;14.494 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 27 ;14.152 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 724 ; 0.066 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3899 ; 0.004 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2976 ; 0.268 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 4809 ; 0.520 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 2109 ; 0.632 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 2096 ; 1.136 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 40 A 624 REMARK 3 ORIGIN FOR THE GROUP (A): 12.3897 -6.0983 -23.4708 REMARK 3 T TENSOR REMARK 3 T11: 0.0109 T22: 0.0202 REMARK 3 T33: 0.0342 T12: 0.0039 REMARK 3 T13: 0.0013 T23: 0.0144 REMARK 3 L TENSOR REMARK 3 L11: 0.2220 L22: 0.6610 REMARK 3 L33: 0.6691 L12: -0.1141 REMARK 3 L13: -0.0396 L23: 0.4899 REMARK 3 S TENSOR REMARK 3 S11: -0.0083 S12: -0.0053 S13: -0.0131 REMARK 3 S21: 0.0539 S22: 0.0411 S23: -0.0647 REMARK 3 S31: 0.0351 S32: 0.0351 S33: -0.0327 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 4APJ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 03-APR-12. REMARK 100 THE DEPOSITION ID IS D_1290051980. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 09-FEB-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.7 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I04 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.979 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS-2M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 20038 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.600 REMARK 200 RESOLUTION RANGE LOW (A) : 71.820 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.7 REMARK 200 DATA REDUNDANCY : 4.800 REMARK 200 R MERGE (I) : 0.13000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 10.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.60 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.74 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.2 REMARK 200 DATA REDUNDANCY IN SHELL : 4.70 REMARK 200 R MERGE FOR SHELL (I) : 0.48000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 1O8A REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 49.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.40 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 50MM SODIUM ACETATE PH 4.7, 15% REMARK 280 PEG4000, 10UM ZNSO4 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.43500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 66.61000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 42.64000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 66.61000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.43500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 42.64000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4710 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25280 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -36.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, P, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 LEU A 37 REMARK 465 VAL A 38 REMARK 465 THR A 39 REMARK 465 SER A 435 REMARK 465 GLU A 436 REMARK 465 GLY A 437 REMARK 465 GLY A 438 REMARK 465 SER A 625 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 72 79.78 -158.05 REMARK 500 GLU A 123 -133.13 59.16 REMARK 500 ARG A 348 -154.31 -74.96 REMARK 500 GLU A 349 80.45 55.30 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 PE4 A 1629 REMARK 610 PE4 A 1630 REMARK 610 PE4 A 1631 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1O86 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ANGIOTENSIN CONVERING ENZYME IN COMPLEX REMARK 900 WITH LISINOPRIL. REMARK 900 RELATED ID: 1O8A RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ANGIOTENSIN CONVERING ENZYME ( NATIVE). REMARK 900 RELATED ID: 1UZE RELATED DB: PDB REMARK 900 COMPLEX OF THE ANTI-HYPERTENSIVE DRUG ENALAPRIL AN THE HUMAN REMARK 900 TESTICULAR ANGIOTENSIN I-CONVERTING ENZYME REMARK 900 RELATED ID: 1UZF RELATED DB: PDB REMARK 900 COMPLEX OF THE ANTI-HYPERTENSIVE DRUG CAPTOPRIL AN THE HUMAN REMARK 900 TESTICULAR ANGIOTENSIN I-CONVERTING ENZYME REMARK 900 RELATED ID: 2C6F RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN SOMATIC ANGIONTENSIN-I CONVERTING ENZYME N DOMAIN REMARK 900 RELATED ID: 2C6N RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN SOMATIC ANGIONTENSIN-I CONVERTING ENZYME N REMARK 900 DOMAIN WITH LISINOPRIL REMARK 900 RELATED ID: 2IUL RELATED DB: PDB REMARK 900 HUMAN TACE G13 MUTANT REMARK 900 RELATED ID: 2IUX RELATED DB: PDB REMARK 900 HUMAN TACE MUTANT G1234 REMARK 900 RELATED ID: 2XY9 RELATED DB: PDB REMARK 900 HUMAN ANGIOTENSIN CONVERTING ENZYME IN COMPLEX WITH PHOSPHINIC REMARK 900 TRIPEPTIDE REMARK 900 RELATED ID: 2XYD RELATED DB: PDB REMARK 900 HUMAN ANGIOTENISN CONVERTING ENZYME N-DOMAIN IN COMPLEX WITH REMARK 900 PHOSPHINIC TRIPEPTIDE REMARK 900 RELATED ID: 2YDM RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF ANGIOTENSIN-I CONVERTING ENZYME IN REMARK 900 COMPLEX WITH A SELENIUM ANALOGUE OF CAPTOPRIL REMARK 900 RELATED ID: 4APH RELATED DB: PDB REMARK 900 HUMAN ANGIOTENSIN-CONVERTING ENZYME IN COMPLEX WITH ANGIOTENSIN-II DBREF 4APJ A 37 625 UNP P12821 ACE_HUMAN 68 656 DBREF 4APJ P 1 11 UNP P01021 BNP_GLOBL 85 95 SEQRES 1 A 589 LEU VAL THR ASP GLU ALA GLU ALA SER LYS PHE VAL GLU SEQRES 2 A 589 GLU TYR ASP ARG THR SER GLN VAL VAL TRP ASN GLU TYR SEQRES 3 A 589 ALA GLU ALA ASN TRP ASN TYR ASN THR ASN ILE THR THR SEQRES 4 A 589 GLU THR SER LYS ILE LEU LEU GLN LYS ASN MET GLN ILE SEQRES 5 A 589 ALA ASN HIS THR LEU LYS TYR GLY THR GLN ALA ARG LYS SEQRES 6 A 589 PHE ASP VAL ASN GLN LEU GLN ASN THR THR ILE LYS ARG SEQRES 7 A 589 ILE ILE LYS LYS VAL GLN ASP LEU GLU ARG ALA ALA LEU SEQRES 8 A 589 PRO ALA GLN GLU LEU GLU GLU TYR ASN LYS ILE LEU LEU SEQRES 9 A 589 ASP MET GLU THR THR TYR SER VAL ALA THR VAL CYS HIS SEQRES 10 A 589 PRO ASN GLY SER CYS LEU GLN LEU GLU PRO ASP LEU THR SEQRES 11 A 589 ASN VAL MET ALA THR SER ARG LYS TYR GLU ASP LEU LEU SEQRES 12 A 589 TRP ALA TRP GLU GLY TRP ARG ASP LYS ALA GLY ARG ALA SEQRES 13 A 589 ILE LEU GLN PHE TYR PRO LYS TYR VAL GLU LEU ILE ASN SEQRES 14 A 589 GLN ALA ALA ARG LEU ASN GLY TYR VAL ASP ALA GLY ASP SEQRES 15 A 589 SER TRP ARG SER MET TYR GLU THR PRO SER LEU GLU GLN SEQRES 16 A 589 ASP LEU GLU ARG LEU PHE GLN GLU LEU GLN PRO LEU TYR SEQRES 17 A 589 LEU ASN LEU HIS ALA TYR VAL ARG ARG ALA LEU HIS ARG SEQRES 18 A 589 HIS TYR GLY ALA GLN HIS ILE ASN LEU GLU GLY PRO ILE SEQRES 19 A 589 PRO ALA HIS LEU LEU GLY ASN MET TRP ALA GLN THR TRP SEQRES 20 A 589 SER ASN ILE TYR ASP LEU VAL VAL PRO PHE PRO SER ALA SEQRES 21 A 589 PRO SER MET ASP THR THR GLU ALA MET LEU LYS GLN GLY SEQRES 22 A 589 TRP THR PRO ARG ARG MET PHE LYS GLU ALA ASP ASP PHE SEQRES 23 A 589 PHE THR SER LEU GLY LEU LEU PRO VAL PRO PRO GLU PHE SEQRES 24 A 589 TRP ASN LYS SER MET LEU GLU LYS PRO THR ASP GLY ARG SEQRES 25 A 589 GLU VAL VAL CYS HIS ALA SER ALA TRP ASP PHE TYR ASN SEQRES 26 A 589 GLY LYS ASP PHE ARG ILE LYS GLN CYS THR THR VAL ASN SEQRES 27 A 589 LEU GLU ASP LEU VAL VAL ALA HIS HIS GLU MET GLY HIS SEQRES 28 A 589 ILE GLN TYR PHE MET GLN TYR LYS ASP LEU PRO VAL ALA SEQRES 29 A 589 LEU ARG GLU GLY ALA ASN PRO GLY PHE HIS GLU ALA ILE SEQRES 30 A 589 GLY ASP VAL LEU ALA LEU SER VAL SER THR PRO LYS HIS SEQRES 31 A 589 LEU HIS SER LEU ASN LEU LEU SER SER GLU GLY GLY SER SEQRES 32 A 589 ASP GLU HIS ASP ILE ASN PHE LEU MET LYS MET ALA LEU SEQRES 33 A 589 ASP LYS ILE ALA PHE ILE PRO PHE SER TYR LEU VAL ASP SEQRES 34 A 589 GLN TRP ARG TRP ARG VAL PHE ASP GLY SER ILE THR LYS SEQRES 35 A 589 GLU ASN TYR ASN GLN GLU TRP TRP SER LEU ARG LEU LYS SEQRES 36 A 589 TYR GLN GLY LEU CYS PRO PRO VAL PRO ARG THR GLN GLY SEQRES 37 A 589 ASP PHE ASP PRO GLY ALA LYS PHE HIS ILE PRO SER SER SEQRES 38 A 589 VAL PRO TYR ILE ARG TYR PHE VAL SER PHE ILE ILE GLN SEQRES 39 A 589 PHE GLN PHE HIS GLU ALA LEU CYS GLN ALA ALA GLY HIS SEQRES 40 A 589 THR GLY PRO LEU HIS LYS CYS ASP ILE TYR GLN SER LYS SEQRES 41 A 589 GLU ALA GLY GLN ARG LEU ALA THR ALA MET LYS LEU GLY SEQRES 42 A 589 PHE SER ARG PRO TRP PRO GLU ALA MET GLN LEU ILE THR SEQRES 43 A 589 GLY GLN PRO ASN MET SER ALA SER ALA MET LEU SER TYR SEQRES 44 A 589 PHE LYS PRO LEU LEU ASP TRP LEU ARG THR GLU ASN GLU SEQRES 45 A 589 LEU HIS GLY GLU LYS LEU GLY TRP PRO GLN TYR ASN TRP SEQRES 46 A 589 THR PRO ASN SER SEQRES 1 P 11 PCA GLY LEU PRO PRO ARG PRO LYS ILE PRO PRO MODRES 4APJ ASN A 109 ASN GLYCOSYLATION SITE MODRES 4APJ PCA P 1 GLU PYROGLUTAMIC ACID HET PCA P 1 8 HET NAG B 1 14 HET NAG B 2 14 HET BMA B 3 11 HET CL A1625 1 HET SO4 A1626 5 HET CL A1627 1 HET CL A1628 1 HET PE4 A1629 16 HET PE4 A1630 16 HET PE4 A1631 16 HET ACT A1635 4 HETNAM PCA PYROGLUTAMIC ACID HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETNAM BMA BETA-D-MANNOPYRANOSE HETNAM CL CHLORIDE ION HETNAM SO4 SULFATE ION HETNAM PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}- HETNAM 2 PE4 ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL HETNAM ACT ACETATE ION HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE HETSYN BMA BETA-D-MANNOSE; D-MANNOSE; MANNOSE HETSYN PE4 POLYETHYLENE GLYCOL PEG4000 FORMUL 2 PCA C5 H7 N O3 FORMUL 3 NAG 2(C8 H15 N O6) FORMUL 3 BMA C6 H12 O6 FORMUL 4 CL 3(CL 1-) FORMUL 5 SO4 O4 S 2- FORMUL 8 PE4 3(C16 H34 O8) FORMUL 11 ACT C2 H3 O2 1- FORMUL 12 HOH *124(H2 O) HELIX 1 1 ASP A 40 ASN A 72 1 33 HELIX 2 2 THR A 74 ARG A 100 1 27 HELIX 3 3 ASP A 103 LEU A 107 5 5 HELIX 4 4 ASN A 109 GLN A 120 1 12 HELIX 5 5 LEU A 122 LEU A 127 5 6 HELIX 6 6 PRO A 128 ALA A 149 1 22 HELIX 7 7 PRO A 163 SER A 172 1 10 HELIX 8 8 LYS A 174 LEU A 194 1 21 HELIX 9 9 PHE A 196 LEU A 210 1 15 HELIX 10 10 ASP A 215 SER A 222 1 8 HELIX 11 11 MET A 223 GLU A 225 5 3 HELIX 12 12 SER A 228 LEU A 240 1 13 HELIX 13 13 LEU A 240 GLY A 260 1 21 HELIX 14 14 TRP A 283 ASN A 285 5 3 HELIX 15 15 ILE A 286 VAL A 291 1 6 HELIX 16 16 ASP A 300 GLN A 308 1 9 HELIX 17 17 THR A 311 LEU A 326 1 16 HELIX 18 18 PRO A 332 SER A 339 1 8 HELIX 19 19 ASN A 374 TYR A 394 1 21 HELIX 20 20 PRO A 398 ARG A 402 5 5 HELIX 21 21 ASN A 406 THR A 423 1 18 HELIX 22 22 THR A 423 LEU A 430 1 8 HELIX 23 23 SER A 439 ILE A 455 1 17 HELIX 24 24 ALA A 456 ASP A 473 1 18 HELIX 25 25 ASN A 480 GLY A 494 1 15 HELIX 26 26 PHE A 506 LYS A 511 5 6 HELIX 27 27 TYR A 520 ALA A 541 1 22 HELIX 28 28 PRO A 546 CYS A 550 5 5 HELIX 29 29 SER A 555 LEU A 568 1 14 HELIX 30 30 PRO A 573 GLY A 583 1 11 HELIX 31 31 ALA A 589 PHE A 596 1 8 HELIX 32 32 PHE A 596 GLY A 611 1 16 SHEET 1 AA 2 THR A 150 CYS A 152 0 SHEET 2 AA 2 CYS A 158 GLN A 160 -1 O LEU A 159 N VAL A 151 SHEET 1 AB 2 ILE A 270 PRO A 271 0 SHEET 2 AB 2 LEU A 495 CYS A 496 1 N CYS A 496 O ILE A 270 SHEET 1 AC 2 SER A 355 ASP A 358 0 SHEET 2 AC 2 PHE A 365 LYS A 368 -1 O ARG A 366 N TRP A 357 SSBOND 1 CYS A 152 CYS A 158 1555 1555 2.04 SSBOND 2 CYS A 352 CYS A 370 1555 1555 2.04 SSBOND 3 CYS A 538 CYS A 550 1555 1555 2.03 LINK ND2 ASN A 109 C1 NAG B 1 1555 1555 1.44 LINK C PCA P 1 N GLY P 2 1555 1555 1.33 LINK O4 NAG B 1 C1 NAG B 2 1555 1555 1.45 LINK O4 NAG B 2 C1 BMA B 3 1555 1555 1.45 CISPEP 1 GLU A 162 PRO A 163 0 2.08 CRYST1 56.870 85.280 133.220 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017584 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011726 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007506 0.00000